Idarubicin (IDA) and high dose cytosine arabinoside (HD ARA-C) for induction therapy for AML and AML arising from myelodysplasia (MDS/AML).

被引：0
|
作者：
Stein, AS [1 ]
ODonnell, MR [1 ]
Nademanee, A [1 ]
Parker, P [1 ]
Lee, J [1 ]
Molina, A [1 ]
Kashyap, A [1 ]
Spielberger, R [1 ]
Smith, E [1 ]
Planas, I [1 ]
Snyder, D [1 ]
Somlo, G [1 ]
Margolin, K [1 ]
Niland, J [1 ]
Forman, SJ [1 ]
机构：
[1] CITY HOPE NATL MED CTR,DUARTE,CA 91010
来源：
BLOOD | 1995年 / 86卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2046 / 2046
页数：1
相关论文
共 50 条
  • [1] TREATMENT OF AML WITH CYTOSINE-ARABINOSIDE (ARA-C) AND ANTHRACYCLINE
    PREISLER, H
    RUSTUM, Y
    HENDERSON, E
    BJORNSSON, S
    HIGBY, D
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1978, 19 (MAR): : 389 - 389
  • [2] Highdose Ara-C/Idarubicin induction and high dose Etoposide/Cytoxan intensification in AML.
    Kurian, S
    Qazilbash, MH
    Lynch, JP
    Beall, CL
    Weisenborn, R
    Bunner, P
    Hobbs, G
    Auber, M
    Ericson, SG
    BLOOD, 2000, 96 (11) : 213B - 213B
  • [3] HIGH-DOSE (HD) CYTOSINE-ARABINOSIDE (ARA-C) FOR THE TREATMENT OF MINIMAL RESIDUAL DISEASE IN ACUTE MYELOGENOUS LEUKEMIA (AML)
    HERZIG, GP
    WOLFF, SN
    HERZIG, RH
    STEIN, RS
    LAZARUS, HM
    MARION, JM
    SPTIZER, TR
    FLEXNER, JM
    PHILLIPS, GL
    LEUKEMIA RESEARCH, 1986, 10 (01) : 87 - 87
  • [4] All trans retinoic acid (ATRA) and low-dose cytosine arabinoside (LD ARA-C) in poor risk AML and MDS.
    Dennis, MW
    Galvani, DW
    Deeble, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 74 - 74
  • [5] COMBINED ACLACINOMYCIN (ACM) AND CYTOSINE-ARABINOSIDE (ARA-C) IN PREVIOUSLY TREATED AML PATIENTS
    MACHOVER, D
    VANDENBULCKE, JM
    BAUME, D
    MISSET, JL
    MATHE, G
    ANTICANCER RESEARCH, 1985, 5 (06) : 635 - 635
  • [6] STANDARD INDUCTION AND LOW-DOSE ARA-C TREATMENT IN PATIENTS OVER 60 WITH AML OR MDS
    VANGEEL, BM
    HUIJGENS, PC
    OSSENKOPPELE, GJ
    WIJERMANS, PW
    LANGENHUIJSEN, MMAC
    NETHERLANDS JOURNAL OF MEDICINE, 1989, 35 (3-4): : 128 - 136
  • [7] EFFICACY OF HIGH-DOSE (HD) AND INTERMEDIATE-DOSE (ID) ARA-C IN PATIENTS WITH SECONDARY LEUKEMIA (SEC AML), REFRACTORY (REF) AML AND RELAPSING (REL) AML
    JAGER, U
    SCHWARZINGER, I
    NEUMANN, E
    BAILER, H
    NIESSNER, H
    HINTERBERGER, W
    BETTELHEIM, P
    PANZER, S
    POLLAK, C
    PABINGERFASCHING, I
    FISCHER, M
    GEISSLER, K
    VIKYDAL, R
    GOSSINGER, H
    LECHNER, K
    BLUT, 1985, 51 (03): : 211 - 211
  • [8] INTERMEDIATE-DOSE ARA-C AND IDARUBICIN FOLLOWED BY LOW-DOSE ARA-C IS PARTICULARLY EFFECTIVE IN UNMAINTAINED RELAPSED AML
    MUUS, P
    DEWITTE, T
    RAEMAEKERS, J
    BLOOD, 1994, 84 (10) : A146 - A146
  • [9] Cytogenetic subgroups of AML and outcome from high dose versus conventional dose Ara-C as part of double induction therapy
    Hiddemann, W
    Fonatsch, C
    Wormann, B
    Heinecke, A
    Sauerland, C
    Scharnhorst, S
    Buchner, T
    BLOOD, 1995, 86 (10) : 1054 - 1054
  • [10] CHEMOTHERAPY FOR ACUTE MYELOCYTIC-LEUKEMIA (AML) WITH CYTOSINE-ARABINOSIDE (ARA-C) AND ADRIAMYCIN (ADR)
    PREISLER, HD
    BJORNSSON, S
    HENDERSON, ES
    BLOOD, 1976, 48 (06) : 982 - 982
12345